DaVita (NYSE:DVA – Get Rating) and Lisata Therapeutics (NASDAQ:LSTA – Get Rating) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, institutional ownership, earnings, valuation and profitability.
Institutional and Insider Ownership
86.5% of DaVita shares are held by institutional investors. Comparatively, 6.0% of Lisata Therapeutics shares are held by institutional investors. 1.0% of DaVita shares are held by insiders. Comparatively, 2.2% of Lisata Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Get DaVita alerts:Analyst Ratings
This is a summary of recent recommendations for DaVita and Lisata Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| DaVita | 1 | 5 | 1 | 0 | 2.00 |
| Lisata Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
DaVita currently has a consensus target price of $86.43, suggesting a potential upside of 12.58%. Lisata Therapeutics has a consensus target price of $15.00, suggesting a potential upside of 353.17%. Given Lisata Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Lisata Therapeutics is more favorable than DaVita.
Volatility and Risk
DaVita has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500. Comparatively, Lisata Therapeutics has a beta of 1.17, meaning that its stock price is 17% more volatile than the S&P 500.
Earnings and Valuation
This table compares DaVita and Lisata Therapeutics' top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| DaVita | $11.61 billion | 0.60 | $560.40 million | $5.78 | 13.28 |
| Lisata Therapeutics | N/A | N/A | -$27.47 million | ($12.23) | -0.27 |
DaVita has higher revenue and earnings than Lisata Therapeutics. Lisata Therapeutics is trading at a lower price-to-earnings ratio than DaVita, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares DaVita and Lisata Therapeutics' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| DaVita | 4.83% | 74.02% | 3.67% |
| Lisata Therapeutics | N/A | -29.53% | -27.96% |
Summary
DaVita beats Lisata Therapeutics on 7 of the 12 factors compared between the two stocks.
About DaVita
(Get Rating)
DaVita, Inc. engages in the provision of medical care services. It operates through the following two segments: US Dialysis and Related Lab Services, and Other-Ancillary Services and Strategic Initiatives. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United States for patients suffering from chronic kidney failure. The Other-Ancillary Services and Strategic Initiatives segment consist primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care, end stage renal disease seamless care organizations, and comprehensive care. The company was founded in 1994 and is headquartered in Denver, CO.
About Lisata Therapeutics
(Get Rating)
Lisata Therapeutics, Inc. develops biopharmaceuticals. It is engaged in the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. It is designed to modify the tumor microenvironment by activating a novel uptake pathway that allows anti-cancer drugs to penetrate solid tumors more effectively. The company is headquartered in Basking Ridge, NJ.
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.